数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

阿里那制药   ARNA
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

股本结构

单位：万股
公告日期 2022-02-23 2022-02-23 2022-01-03 2022-01-03 2021-11-04 2021-11-04
证券总股本 6165.94 6156.41 6156.41 6138.66 6132.83 6128.02
普通股本 6165.94 6156.41 6156.41 6138.66 6132.83 6128.02
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2022-02-17 2021-12-31 2021-12-30 2021-12-10 2021-10-28 2021-09-30
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2022-02-23 6165.94 未披露 定期报告 2022-02-17
2022-02-23 6156.41 未披露
更多>>
From December 31, 2020 to December 31, 2021 Shares issued from stock plans, net of payroll taxes paid Issuance of common stock under the ATM facility, net
2021-12-31
2022-01-03 6156.41 未披露 定期报告 2021-12-30
2022-01-03 6138.66 未披露 定期报告 2021-12-10
2021-11-04 6132.83 未披露 定期报告 2021-10-28
2021-11-04 6128.02 未披露
更多>>
From June 30, 2021 to September 30, 2021 Shares issued from stock plans, net of payroll taxes paid
2021-09-30
2021-08-05 6107.44 未披露 定期报告 2021-07-29
2021-08-05 6104.50 未披露
更多>>
From March 31, 2021 to June 30, 2021 Shares issued from stock plans, net of payroll taxes paid
2021-06-30
2021-05-05 6069.62 未披露 定期报告 2021-04-29
2021-04-27 6066.03 未披露 定期报告 2021-04-15
2021-05-05 6061.91 未披露
更多>>
From December 31, 2020 to March 31, 2021 Shares issued from stock plans, net of payroll taxes paid Issuance of common stock under the ATM facility, net
2021-03-31
2021-02-23 6033.46 未披露 定期报告 2021-02-18
2021-02-23 5861.12 未披露
更多>>
From December 31,2019 to December 31,2020 Issuance of common stock to underwriters, net Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards
2020-12-31
2020-11-09 5816.40 未披露 定期报告 2020-11-04
2020-11-09 5804.38 未披露
更多>>
From June 30, 2020 to September 30, 2020 Issuance of common stock upon exercise of options
2020-09-30
2020-08-05 5764.69 未披露 定期报告 2020-07-31
2020-08-05 5757.49 未披露
更多>>
From March 31, 2020 to June 30, 2020 Issuance of common stock to underwriters, net Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards
2020-06-30
2020-06-01 5579.67 未披露
更多>>
1.Common stock to be offered by the company 5,500,000 shares. 2.The number of shares of common stock outstanding immediately following this offering set forth above is based on 50,296,714 shares of common stock outstanding as of March 31, 2020.
2020-06-01
2020-05-07 5033.70 未披露 定期报告 2020-05-01
2020-04-29 5031.15 未披露 定期报告 2020-04-20
2020-05-07 5029.67 未披露
更多>>
from December 31, 2019 to March 31, 2020 Issuance of common stock upon exercise of options
2020-03-31
2020-02-27 5024.91 未披露 定期报告 2020-02-21
2020-02-27 5017.10 未披露
更多>>
from December 31, 2018 to December 31, 2019 Issuance of common stock upon exercise of options Issuance of common stock upon vesting of restricted stock unit awards
2019-12-31
2019-11-08 5010.71 未披露 定期报告 2019-11-01
2019-11-08 4998.45 未披露
更多>>
from June 30, 2019 to September 30, 2019 Issuance of common stock upon exercise of options
2019-09-30
2019-08-09 4982.52 未披露 定期报告 2019-08-02
2019-08-09 4980.26 未披露
更多>>
From March 31, 2019 to June 30, 2019 Issuance of common stock upon exercise of options Issuance of common stock upon vesting of restricted stock unit awards
2019-06-30
2019-04-30 4957.01 未披露 定期报告 2019-04-24
2019-05-09 4954.86 未披露
更多>>
from December 31, 2018 to March 31, 2019 Issuance of common stock upon exercise of options
2019-03-31
2019-02-28 4946.28 未披露 定期报告 2019-02-22
2019-02-28 4942.30 未披露
更多>>
from December 31, 2017 to December 31, 2018 Issuance of common stock to underwriters, net Issuance of common stock upon exercise of options Issuance of common stock upon vesting of restricted stock unit awards
2018-12-31
2018-11-08 4940.65 未披露 定期报告 2018-11-02
2018-08-07 4934.82 未披露 定期报告 2018-08-02
2018-05-09 4923.41 未披露 定期报告 2018-05-04
2018-04-30 4922.67 未披露 定期报告 2018-04-24
2018-04-30 4919.67 未披露 定期报告 2018-03-31
2018-03-14 3940.18 未披露 定期报告 2018-03-09
2018-03-14 3928.07 未披露
更多>>
from December 31, 2016 to December 31, 2017 Issuance of common stock to underwriters, net Issuance of common stock under the ATM facility, net Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards
2017-12-31
2017-11-08 3926.34 未披露 定期报告 2017-11-03
2017-08-08 3922.02 未披露 定期报告 2017-08-04
2017-06-14 3170.00 未披露
更多>>
Arena Pharmaceuticals, Inc., today announced a reverse stock split of Arena's outstanding common shares at an exchange ratio of 1-for-10, and a change in the number of authorized shares of common stock to 73.5 million shares. Arena's Board of Directors had previously directed that the proposal be submitted to the shareholders for approval and has subsequently determined that the reverse stock split will take effect at 5:00pm ET on June 16, 2017. Beginning with the opening of trading on June 19, 2017, the Company's common stock will trade on a split-adjusted basis.As a result of the reverse split, there will be approximately 31.7 million shares of common stock issued and outstanding.
2017-06-19
2017-04-28 31743.56 未披露 定期报告 2017-04-24
2017-04-28 24714.87 未披露 定期报告 2017-03-31
2017-03-15 24546.91 未披露 定期报告 2017-03-10
2017-03-15 24340.08 未披露
更多>>
from December 31, 2015 to December 31, 2016 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock unit awards
2016-12-31
2016-11-09 24331.38 未披露 定期报告 2016-11-04
2016-08-09 24325.61 未披露 定期报告 2016-08-04
2016-04-28 24304.47 未披露 定期报告 2016-04-15
2016-04-28 24295.49 未披露 定期报告 2016-03-31
2016-02-29 24287.12 未披露
更多>>
from December 31, 2014 to December 31, 2015 Issuance of common stock to underwriters Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock unit awards
2015-12-31
2015-11-09 24254.96 未披露 定期报告 2015-11-04
2015-08-07 24224.17 未披露 定期报告 2015-08-04
2015-05-11 24203.98 未披露 定期报告 2015-05-06
2015-04-29 24203.55 未披露 定期报告 2015-04-14
2015-05-11 24200.00 未披露 定期报告 2015-03-31
2015-03-02 24146.30 未披露 定期报告 2015-02-24
2015-01-20 22046.30 未披露 定期报告 2015-01-16
2015-03-02 22032.16 未披露
更多>>
from December 31, 2013 to December 31, 2014 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock unit awards
2014-12-31
2014-11-06 22011.50 未披露 定期报告 2014-11-03
2014-08-06 21983.58 未披露 定期报告 2014-07-31
2014-08-01 21980.00 未披露 定期报告 2014-06-30
2014-05-12 21965.00 未披露 定期报告 2014-05-06
2014-05-28 21955.60 未披露 定期报告 2014-04-15
2014-04-29 21948.47 未披露 定期报告 2014-03-31
2014-03-03 21926.00 未披露 定期报告 2014-02-24
2014-03-03 21881.62 未披露
更多>>
from December 31, 2012 to December 31, 2013 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock unit awards Issuance of common stock upon exercise of Series B warrant
2013-12-31
2013-11-12 21857.41 未披露 定期报告 2013-11-07
2013-08-05 21825.37 未披露 定期报告 2013-07-30
2013-05-09 21777.71 未披露 定期报告 2013-04-30
2013-03-01 21748.92 未披露 定期报告 2013-02-20
2013-03-01 21747.65 未披露
更多>>
from December 31, 2011 to December 31, 2012 Issuance of Series D preferred stock to Deerfield Issuance of common stock to Deerfield upon conversion of Series D preferred stock Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock under equity line of credit Issuance of common stock in public offering, net of offering costs of $3,875 Issuance of common stock to Deerfield Issuance of common stock upon exercise of Deerfield warrants Retirement of treasury stock
2012-12-31
2012-11-09 21729.30 未披露 定期报告 2012-11-01
2012-08-09 21681.80 未披露 定期报告 2012-08-06
2012-05-02 18250.08 未披露 定期报告 2012-05-01
2012-03-15 18042.24 未披露 定期报告 2012-03-09
2012-03-15 14609.28 未披露
更多>>
from December 31, 2010 to December 31, 2011 Issuance of common stock under employee stock purchase plan Issuance of common stock to Deerfield Issuance of common stock to Deerfield upon conversion of Series C preferred stock Restricted shares released from deferred compensation plan
2011-12-31
2011-11-09 14602.48 未披露 定期报告 2011-11-02
2011-08-09 14596.21 未披露 定期报告 2011-08-05
2011-05-10 14589.43 未披露 定期报告 2011-05-02
2011-03-15 12151.58 未披露
更多>>
from December 31, 2009 to December 31, 2010 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock under equity financing arrangement Issuance of common stock to Deerfield Restricted shares released from deferred compensation plan
2010-12-31
2010-11-09 12141.15 未披露 定期报告 2010-11-05
2010-08-09 11234.65 未披露 定期报告 2010-08-05
2010-05-07 10122.69 未披露 定期报告 2010-05-05
2010-03-16 10112.56 未披露 定期报告 2010-03-10
2010-03-16 9281.39 未披露
更多>>
from December 31, 2008 to December 31, 2009 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plans Issuance of common stock under equity financing commitment Issuance of common stock in public offering, net of offering costs of $2,400 Restricted shares released from deferred compensation plan
2009-12-31
2009-03-16 7419.45 未披露 定期报告 2009-03-13
2009-03-16 7413.45 未披露
更多>>
from December 31, 2007 to December 31, 2008 Issuance of common stock upon exercise of options Issuance of common stock under the employee stock purchase plan Issuance of common stock to Siegfried
2008-12-31
2008-03-05 7375.98 未披露
更多>>
There were 73,759,776 shares of our common stock outstanding as of February 29, 2008. The outstanding shares of our Series B-1 Preferred are convertible into up to 5,481,740 shares of common stock at $7.50 per share of common stock. The outstanding shares of our Series B-2 Preferred are convertible into up to 1,829,909 shares of common stock at $7.00 per share of common stock.
2008-02-29
2008-03-05 7226.03 0.47
更多>>
from December 31, 2006 to December 31, 2007 Issuance of common stock upon exercise of options Issuance of common stock under the employee stock purchase plan Issuance of common stock to Merck Issuance of common stock in public offering, net of offering costs of $5,847 Restricted shares released from deferred compensation plan
2007-12-31
2007-03-06 6081.66 未披露
更多>>
There were 60,816,605 shares of our common stock outstanding as of February 28, 2007. The outstanding shares of our Series B-1 Preferred are convertible into up to 5,266,809 shares of common stock at $7.50 per share of common stock. The outstanding shares of our Series B-2 Preferred are convertible into up to 1,758,161 shares of common stock at $7.00 per share of common stock.
2007-02-28
2007-03-06 6077.14 0.47
更多>>
from December 31, 2005 to December 31, 2006 Issuance of common stock upon exercise of options Issuance of common stock under the employee stock purchase plan Issuance of restricted stock Issuance of common stock upon exercise of warrants Issuance of common stock in public offering, net of offering costs of $10,809 Issuance of common stock in public offering, net of offering costs of $9,574 Restricted shares released from deferred compensation plan
2006-12-31
2006-03-07 4626.49 未披露
更多>>
There were 46,264,854 shares of our common stock outstanding as of February 28, 2006. The outstanding shares of our Series B-1 Preferred are convertible into up to 5,060,306 shares of common stock at $7.50 per share of common stock. The outstanding shares of our Series B-2 Preferred are convertible into up to 1,689,226 shares of common stock at $7.00 per share of common stock.
2006-02-28
2006-03-07 3549.06 0.47
更多>>
from December 31, 2004 to December 31, 2005 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock under the employee stock purchase plan Issuance of restricted stock, net of cancellations Issuance of common stock in public offering, net of offering costs of $3,599,214 Restricted shares released from company deferred compensation plan
2005-12-31
2005-03-02 3520.59 未披露
更多>>
There were 35,205,869 shares of our common stock outstanding as of February 15, 2005. The outstanding shares of our Series B-1 Convertible Preferred Stock are convertible into up to 4,861,899 shares of common stock at $7.50 per share of common stock.
2005-02-15
2005-03-02 2656.64 0.35
更多>>
from December 31, 2003 to December 31, 2004 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock under the employee stock purchase plan Cancellations of restricted stock, net of issuances Issuance of common stock to Merck Restricted shares deferred in company deferred compensation plan, net of distributions and forfeitures
2004-12-31
2004-03-01 2555.90 未披露 定期报告 2004-02-01
2004-03-01 2554.84 0.35
更多>>
from December 31, 2002 to December 31, 2003 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock, warrants and units warrants related to preferred financing Issuance of common stock under the employee stock purchase plan Issuance of restricted stock, net of cancellations Repurchase of common shares Restricted shares deferred in company deferred compensation plan
2003-12-31
2003-03-28 2844.29 未披露 定期报告 2003-03-03
2003-03-28 2774.65 未披露
更多>>
from December 31, 2001 to December 31, 2002 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock under the employee stock purchase plan
2002-12-31
2002-03-15 2758.62 未披露 定期报告 2002-02-01
2002-03-15 2758.50 未披露
更多>>
from December 31, 2000 to December 31, 2001 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock upon exercise of options under the employee stock purchase plan Issuance of common stock in public offering, net of offering costs of $7,599,970
2001-12-31
2001-03-21 2269.69 未披露 定期报告 2001-03-01
2001-03-21 2268.83 未披露
更多>>
from December 31, 1999 to December 31, 2000 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock upon exercise of warrants Conversion of convertible note into common stock Issuance of common stock in initial public offering, net of offering costs of $10,274,000 Conversion of preferred stock to common stock upon closing of initial public offering
2000-12-31
From December 31, 2020 to December 31, 2021 Shares issued from stock plans, net of payroll taxes paid Issuance of common stock under the ATM facility, net
From June 30, 2021 to September 30, 2021 Shares issued from stock plans, net of payroll taxes paid
From March 31, 2021 to June 30, 2021 Shares issued from stock plans, net of payroll taxes paid
From December 31, 2020 to March 31, 2021 Shares issued from stock plans, net of payroll taxes paid Issuance of common stock under the ATM facility, net
From December 31,2019 to December 31,2020 Issuance of common stock to underwriters, net Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards
From June 30, 2020 to September 30, 2020 Issuance of common stock upon exercise of options
From March 31, 2020 to June 30, 2020 Issuance of common stock to underwriters, net Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards
1.Common stock to be offered by the company 5,500,000 shares. 2.The number of shares of common stock outstanding immediately following this offering set forth above is based on 50,296,714 shares of common stock outstanding as of March 31, 2020.
from December 31, 2019 to March 31, 2020 Issuance of common stock upon exercise of options
from December 31, 2018 to December 31, 2019 Issuance of common stock upon exercise of options Issuance of common stock upon vesting of restricted stock unit awards
from June 30, 2019 to September 30, 2019 Issuance of common stock upon exercise of options
From March 31, 2019 to June 30, 2019 Issuance of common stock upon exercise of options Issuance of common stock upon vesting of restricted stock unit awards
from December 31, 2018 to March 31, 2019 Issuance of common stock upon exercise of options
from December 31, 2017 to December 31, 2018 Issuance of common stock to underwriters, net Issuance of common stock upon exercise of options Issuance of common stock upon vesting of restricted stock unit awards
from December 31, 2016 to December 31, 2017 Issuance of common stock to underwriters, net Issuance of common stock under the ATM facility, net Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards
Arena Pharmaceuticals, Inc., today announced a reverse stock split of Arena's outstanding common shares at an exchange ratio of 1-for-10, and a change in the number of authorized shares of common stock to 73.5 million shares. Arena's Board of Directors had previously directed that the proposal be submitted to the shareholders for approval and has subsequently determined that the reverse stock split will take effect at 5:00pm ET on June 16, 2017. Beginning with the opening of trading on June 19, 2017, the Company's common stock will trade on a split-adjusted basis.As a result of the reverse split, there will be approximately 31.7 million shares of common stock issued and outstanding.
from December 31, 2015 to December 31, 2016 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock unit awards
from December 31, 2014 to December 31, 2015 Issuance of common stock to underwriters Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock unit awards
from December 31, 2013 to December 31, 2014 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock unit awards
from December 31, 2012 to December 31, 2013 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock upon vesting of restricted stock unit awards Issuance of common stock upon exercise of Series B warrant
from December 31, 2011 to December 31, 2012 Issuance of Series D preferred stock to Deerfield Issuance of common stock to Deerfield upon conversion of Series D preferred stock Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock under equity line of credit Issuance of common stock in public offering, net of offering costs of $3,875 Issuance of common stock to Deerfield Issuance of common stock upon exercise of Deerfield warrants Retirement of treasury stock
from December 31, 2010 to December 31, 2011 Issuance of common stock under employee stock purchase plan Issuance of common stock to Deerfield Issuance of common stock to Deerfield upon conversion of Series C preferred stock Restricted shares released from deferred compensation plan
from December 31, 2009 to December 31, 2010 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plan Issuance of common stock under equity financing arrangement Issuance of common stock to Deerfield Restricted shares released from deferred compensation plan
from December 31, 2008 to December 31, 2009 Issuance of common stock upon exercise of options Issuance of common stock under employee stock purchase plans Issuance of common stock under equity financing commitment Issuance of common stock in public offering, net of offering costs of $2,400 Restricted shares released from deferred compensation plan
from December 31, 2007 to December 31, 2008 Issuance of common stock upon exercise of options Issuance of common stock under the employee stock purchase plan Issuance of common stock to Siegfried
There were 73,759,776 shares of our common stock outstanding as of February 29, 2008. The outstanding shares of our Series B-1 Preferred are convertible into up to 5,481,740 shares of common stock at $7.50 per share of common stock. The outstanding shares of our Series B-2 Preferred are convertible into up to 1,829,909 shares of common stock at $7.00 per share of common stock.
from December 31, 2006 to December 31, 2007 Issuance of common stock upon exercise of options Issuance of common stock under the employee stock purchase plan Issuance of common stock to Merck Issuance of common stock in public offering, net of offering costs of $5,847 Restricted shares released from deferred compensation plan
There were 60,816,605 shares of our common stock outstanding as of February 28, 2007. The outstanding shares of our Series B-1 Preferred are convertible into up to 5,266,809 shares of common stock at $7.50 per share of common stock. The outstanding shares of our Series B-2 Preferred are convertible into up to 1,758,161 shares of common stock at $7.00 per share of common stock.
from December 31, 2005 to December 31, 2006 Issuance of common stock upon exercise of options Issuance of common stock under the employee stock purchase plan Issuance of restricted stock Issuance of common stock upon exercise of warrants Issuance of common stock in public offering, net of offering costs of $10,809 Issuance of common stock in public offering, net of offering costs of $9,574 Restricted shares released from deferred compensation plan
There were 46,264,854 shares of our common stock outstanding as of February 28, 2006. The outstanding shares of our Series B-1 Preferred are convertible into up to 5,060,306 shares of common stock at $7.50 per share of common stock. The outstanding shares of our Series B-2 Preferred are convertible into up to 1,689,226 shares of common stock at $7.00 per share of common stock.
from December 31, 2004 to December 31, 2005 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock under the employee stock purchase plan Issuance of restricted stock, net of cancellations Issuance of common stock in public offering, net of offering costs of $3,599,214 Restricted shares released from company deferred compensation plan
There were 35,205,869 shares of our common stock outstanding as of February 15, 2005. The outstanding shares of our Series B-1 Convertible Preferred Stock are convertible into up to 4,861,899 shares of common stock at $7.50 per share of common stock.
from December 31, 2003 to December 31, 2004 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock under the employee stock purchase plan Cancellations of restricted stock, net of issuances Issuance of common stock to Merck Restricted shares deferred in company deferred compensation plan, net of distributions and forfeitures
from December 31, 2002 to December 31, 2003 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock, warrants and units warrants related to preferred financing Issuance of common stock under the employee stock purchase plan Issuance of restricted stock, net of cancellations Repurchase of common shares Restricted shares deferred in company deferred compensation plan
from December 31, 2001 to December 31, 2002 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock under the employee stock purchase plan
from December 31, 2000 to December 31, 2001 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock upon exercise of options under the employee stock purchase plan Issuance of common stock in public offering, net of offering costs of $7,599,970
from December 31, 1999 to December 31, 2000 Issuance of common stock upon exercise of options, net of repurchases Issuance of common stock upon exercise of warrants Conversion of convertible note into common stock Issuance of common stock in initial public offering, net of offering costs of $10,274,000 Conversion of preferred stock to common stock upon closing of initial public offering